ArticleCNS neuroscience & therapeutics2026
Pharmacovigilance Insights Into Immune Checkpoint Inhibitor-Induced Risk of Paraneoplastic Syndrome: A Large-Scale Real World Study.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pharmacovigilance Insights Into Immune Checkpoint Inhibitor-Induced Risk of Paraneoplastic Syndrome: A Large-Scale Real World Study.CNS neuroscience & therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundImmune checkpoint inhibitor (ICI)-associated paraneoplastic syndromes (PS) represent a rare but potentially life-threatening adverse event. Despite the widespread use of ICIs in cancer treatment, the clinical characteristics and risk profiles of PS across different treatment regimens remain incompletely characterized.
methodsWe analyzed FAERS data (Jan 2011-Jun 2024) to identify PS cases potentially related to ICI use. Reporting odds ratios (RORs) were calculated to evaluate safety signals. Clinical features, time-to-onset, and outcomes were analyzed across different ICI regimens.
resultsAmong 162,493 ICI-associated adverse event reports, 179 PS cases were identified. Disproportionate reporting of PS was observed with PD-1 inhibitors (ROR 21.77, 95% CI 16.36-28.97), PD-L1 inhibitors (ROR 23.33, 95% CI 14.13-38.41), nivolumab plus ipilimumab (ROR 24.21, 95% CI 18.07-32.42), and durvalumab plus tremelimumab (ROR 24.55, 95% CI 18.73-32.79). PS onset showed a bimodal distribution, with a median time to onset of 6 days, where 42.31% occurring within 30 days and 23.08% after 360 days of treatment initiation. Combination therapy, particularly durvalumab plus tremelimumab, was associated with higher rates of severe outcomes (27.8%). In patients with PS related to ICI therapy, those with lung malignancies are the most commonly represented group.
conclusionsThis analysis reveals distinct temporal patterns and safety signals of ICI-associated PS, with higher reporting rates and severity in combination therapy. These findings provide important insights for clinical monitoring strategies and highlight the need for increased vigilance during specific risk windows, particularly in patients receiving combination therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.